Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
Authors Zheng L, Cao C, Cheng G, Hu Q, Chen X
Received 19 September 2017
Accepted for publication 17 October 2017
Published 16 November 2017 Volume 2017:10 Pages 5483—5487
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 4
Editor who approved publication: Dr Yao Dai
Linfeng Zheng,1,* Caineng Cao,2,3,* Guoping Cheng,1 Qiaoying Hu,2,3 Xiaozhong Chen2,3
1Department of Pathology, 2Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 3Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Background and objective: The aim of this study was to evaluate the expression of cytomembranic programmed death-ligand 1 (PD-L1) and its clinical significance in locoregionally advanced nasopharyngeal carcinoma (NPC).
Patients and methods: Formalin-fixed, paraffin-embedded tissue biopsies from 85 patients with histological diagnosis of locoregionally advanced NPC treated with radical intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy were studied. By using immunohistochemistry staining, expressions of cytomembranic PD-L1 on tumor cells were detected.
Results: After a median follow-up duration of 65.8 months, 7 (8.2%), 5 (5.9%), and 5 (5.9%) patients suffered from local failure, regional failure, and distant metastases, respectively. The 5-year local failure-free survival, regional failure-free survival, distant failure-free survival, and overall survival (OS) rates were 90.9%, 94.8%, 94.0%, and 92.2%, respectively. Our results revealed that a high expression of cytomembranic PD-L1 was correlated with shorter OS (5y-OS: 82.5% vs 97.6%, P=0.022). In the multivariate analysis, only the cytomembranic PD-L1 was an independent prognostic factor for OS (hazard ratio: 6.176, 95% confidence interval, 1.166–32.710, P=0.032).
Conclusion: Cytomembranic PD-L1 expression levels correlated with OS in locoregionally advanced NPC. Agreement between different methods is needed for further application of PD-L1 biomarker assays in NPC.
Keywords: nasopharyngeal carcinoma, programmed death-ligand 1, PD-L1, prognosis, overall survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]